STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #87 by analyst upside · 2026-06-27
TPST
Tempest Therapeutics, Inc.
Healthcare · Market Cap $16M · P/E 0x
ANALYST PRICE TARGET
+918.5%
implied upside to consensus target
Current Price $1.08
Consensus Target $11.0
Bull Target $11.0
Bear Target $11.0
Analysts Covering 1
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $1.02
52-Week High $12.23
YTD Return -63.4%
FUNDAMENTALS
Market Cap $16M
P/E Ratio (TTM) N/A
Forward P/E -0.9x
EPS (TTM) $-5.70
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.02
52-Week High $12.23
Current Price $1.08
Bear Target $11.0
Bull Target $11.0
● Now $1.08 ● Target $11.0
TRADING DATA
Avg Volume 200K
YTD Return -63.4%
Analyst Count 1
Consensus Buy
Upside to Target +918.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Tempest Therapeutics, Inc. (TPST) is currently trading at $1.08 with a Wall Street consensus price target of $11.0, implying potential upside of 918.5% over the next 12 months. 1 analysts currently cover TPST, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $11.0.

TPST operates in the Healthcare sector with a market capitalisation of $16M. The stock is down 63.4% year-to-date and is currently trading near the lower end of its 52-week range of $1.02 – $12.23.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TPST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ↑ Upgrade
Neutral → Buy 2026-01-22 31% win rate (48 calls)
Scotiabank ↓ Downgrade
Sector Outperform → Sector Perform 2025-04-10 20% win rate (5 calls)
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2025-04-10 31% win rate (48 calls)
Scotiabank — Reiterated
Sector Outperform → Sector Outperform 2025-03-28 20% win rate (5 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-03-28 31% win rate (48 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2024-11-13 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-11-13 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-10-10 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →